VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIA

患有精神分裂症的吸烟者吸食的尼古丁含量非常低

• 批准号: 8379278
• 负责人: JENNIFER W. TIDEY
• 金额: $ 26.4万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-15 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8379278
• 关键词: Abstinence; Acute; Aftercare; Behavioral; Benefits and Risks; Biological Markers; Cigarette; Complement; Dose; General Population; Health Policy; Human; Instruction; Knowledge; Laboratory Study; Longevity; Measures; Methods; Minority; Moods; Morbidity - disease rate; Neurobehavioral Manifestations; Nicotine; Pattern; Performance; Phase; Population; Prevalence; Public Health; Randomized; Schizophrenia; Self Medication; Smoke; Smoker; Smoking; Symptoms; Time; Tobacco; Tobacco use; United States; Withdrawal; Withdrawal Symptom; Withholding Treatment; cigarette smoking; cognitive function; craving; cue reactivity; innovation; mortality; negative mood; response; satisfaction; severe mental illness; smoking cessation; treatment duration

Nearly half of the tobacco consumed in the United States is smoked by people with psychiatric illness. In particular, smokers with schizophrenia (SWS) infrequently attempt and attain sustained smoking abstinence and have a 25-year shorter lifespan due to smoking-related illness. SWS are in dire need of effective smoking treatment and are not benefiting from treatments that are currently available. Reducing the nicotine content of cigarettes to non-addicting levels is an innovative strategy that has the potential to significantly reduce tobacco-related morbidity and mortality in this population. In evaluating the potential impact of this strategy, one critical knowledge gap that was identified is whether this strategy would be effective in smokers with serious mental illness, who are more nicotine-dependent than other smokers and who may smoke for self-medication purposes. We are currently studying the acute effects of VLNC cigarettes in SWS, with promising results showing that use of these cigarettes reverses abstinence-induced cigarette craving, withdrawal-related negative mood and usual-brand smoking. Furthermore, SWS rate the subjective effects VLNC cigarettes highly, indicating that such an approach may be acceptable to SWS. However, the effects of prolonged use of VLNC cigarettes on smoking tiehavior, psychiatric symptoms and cognitive functioning in SWS are unknown. This study would be the first to examine whether a regulatory approach of reducing the nicotine content of cigarettes to non-addicting levels is a viable method of reducing smoking in this population. Smokers will be randomized to one of two experimental conditions: 1) very low nicotine content (VLNC) cigarettes with a 0.06 mg nicotine yield (actual dose to be determined by Project 1; n = 40), or 2) normal nicotine content cigarettes (n = 40). Over the 2-week baseline and 6-week treatment phases, subjects will be assessed for patterns of tobacco use, biomarkers of exposure, subjective responses (e.g., satisfaction, craving, withdrawal symptoms), psychiatric symptoms, cognitive performance, smoking cue reactivity and smoking topography. At the end of the 6-week treatment period, subjective and behavioral responses to smoking abstinence will be assessed. The results from this study will describe the possible risks and benefits to smokers with schizophrenia of dramatically reducing the nicotine content of cigarettes. This project will complement and use similar measures as Projects 1 and 2. RELEVANCE (See instructions); There is an unusually high rate of cigarette smoking and correspondingly high rates of smoking-related morbidity and mortality in smokers with schizophrenia. This project will investigate the effects of 6-week use of very low nicotine content cigarettes on smoking, mood, psychiatric symptoms, cognitive functioning and other measures in smokers with schizophrenia. This information will help to determine whether a public health policy of limiting the nicotine content of cigarettes to very low levels would be effective and safe for these smokers

在美国消耗的烟草中，近一半是由精神病患者吸烟。在 特别是，精神分裂症（SWS）的吸烟者很少尝试并获得持续的戒烟 由于吸烟相关的疾病，其寿命短25年。 SWS迫切需要有效 吸烟治疗，并不能从目前可用的治疗中受益。减少尼古丁 香烟含量到非成瘾水平是一种创新的策略，有可能显着 降低该人群中与烟草相关的发病率和死亡率。在评估这一点的潜在影响时 策略，确定的一个关键知识差距是该策略是否对吸烟者有效 患有严重的精神疾病，比其他吸烟者更依赖尼古丁，他们可能会吸烟 自我药物目的。我们目前正在研究SWS中VLNC香烟的急性影响， 有希望的结果表明，这些香烟的使用逆转了禁欲引起的香烟的渴望， 与戒断相关的负面情绪和通常的品牌吸烟。此外，SWS对主观效果进行评分 VLNC香烟高度高，表明SWS可能可以接受这种方法。但是，效果 长期使用VLNC香烟在吸烟中，精神病症状和认知功能 SWS是未知的。这项研究将是第一个检查的调节方法是否减少 香烟的尼古丁含量到非成瘾水平是减少吸烟的一种可行方法 人口。吸烟者将被随机分为两个实验条件之一：1）非常低的尼古丁含量 （VLNC）具有0.06 mg尼古丁产率的香烟（实际剂量由项目1； n = 40确定），或2） 正常尼古丁含量香烟（n = 40）。在2周的基线和6周的治疗阶段， 将评估受试者的烟草使用模式，暴露的生物标志物，主观反应（例如， 满意度，渴望，戒断症状），精神病症状，认知表现，吸烟提示 反应性和吸烟地形。在6周的治疗期结束时，主观和行为 将评估对戒烟的反应。这项研究的结果将描述可能 精神分裂症的吸烟者的风险和利益大大减少了香烟的尼古丁含量。 该项目将补充和使用与项目1和2的类似措施。 相关性（请参阅说明）； 吸烟率异常高，与吸烟有关 精神分裂症吸烟者的发病率和死亡率。该项目将调查6周使用的影响 关于吸烟，情绪，精神症状，认知功能和 精神分裂症吸烟者的其他措施。这些信息将有助于确定公众是否 将香烟的尼古丁含量限制为非常低的健康政策将有效且安全 这些吸烟者